1666.7000 21.70 (1.32%)
NSE Apr 16, 2025 15:31 PM
Volume: 129.4K
 

1666.70
1.32%
ICICI Securities Limited
Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests. In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25.
Metropolis Healthcare Ltd. is trading below its 100 day SMA of 1838.0
More from Metropolis Healthcare Ltd.
Recommended